Absci Corp (ABSI)vsInsmed Inc (INSM)
ABSI
Absci Corp
$2.92
-2.99%
HEALTHCARE · Cap: $445.10M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 21443% more annual revenue ($606.42M vs $2.81M). ABSI leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
ABSI
Avoid25
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -55.7% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABSI
The strongest argument for ABSI centers on Debt/Equity, Price/Book.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ABSI
The primary concerns for ABSI are EPS Growth, Market Cap, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
ABSI profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
ABSI carries more volatility with a beta of 2.13 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
ABSI generates stronger free cash flow (-26M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Absci Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Absci Corp (ABSI) is a pioneering biotechnology company revolutionizing drug discovery through its state-of-the-art AI-driven biology platform. Focused on the rapid generation of high-quality proteins and therapeutic candidates, Absci significantly accelerates traditional development timelines while lowering associated costs. The company is dedicated to transforming the biopharmaceutical landscape by equipping partners with innovative tools to develop and manufacture next-generation therapies with unparalleled efficiency and precision. With a robust pipeline of collaborations and proprietary initiatives, Absci is strategically positioned to drive significant advancements in disease treatment and modern drug development practices.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?